433226-06-3

Basic information

• Product Name: ETHYL 2-AMINO-5-BROMONICOTINATE
• Synonyms: ETHYL 2-AMINO-5-BROMONICOTINATE;Ethyl 2-amino-5-bromopyridine-3-carboxylate;Ethyl 2-amino-5-bromopyridine-3-carboxylate, 2-Amino-5-bromo-3-(ethoxycarbonyl)pyridine;3-Pyridinecarboxylic acid, 2-aMino-5-broMo-, ethyl ester
• CAS NO: 433226-06-3
• Molecular Formula: C8H9BrN2O2
• Molecular Weight: 245.07
• Mol File: 433226-06-3.mol
• Article Data: 14

Chemical Properties

• Melting Point: 139-141°
• Boiling Point: 290.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.575±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.59±0.49(Predicted)
• CAS DataBase Reference: ETHYL 2-AMINO-5-BROMONICOTINATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-AMINO-5-BROMONICOTINATE(433226-06-3)
• EPA Substance Registry System: ETHYL 2-AMINO-5-BROMONICOTINATE(433226-06-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 433226-06-3(Hazardous Substances Data)

Usage

General Description

ETHYL 2-AMINO-5-BROMONICOTINATE is a chemical compound with the molecular formula C8H8BrN3O2. It is a derivative of nicotinic acid and contains an ethyl ester group, an amino group, and a bromine atom attached to the aromatic ring. ETHYL 2-AMINO-5-BROMONICOTINATE has been studied for its potential use in medicinal and pharmaceutical applications, particularly in the development of new drugs and pharmaceutical products. Its properties and potential biological activities make it a subject of interest for further research in the field of organic chemistry and pharmaceutical sciences.

Upstream product

• 13362-26-0 2-aminopyridine-3-carboxylic acid ethyl ester 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 14667-47-1 methyl 2-aminonicotinate 
• 114078-88-5 5-bromo-1,2,3-triazine 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 1801262-20-3 6-bromo-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylic acid methyl ester 
• 1215787-31-7 6-bromo-4-chloropyrido[2,3-d]pyrimidine 
• 155690-79-2 6-bromo-3H,4H-pyrido[2,3-d]pyrimidin-4-one 

Relevant articles and documents

Synthesis of 5H-pyrido[3,2-b]pyrrolizin-5-one tripentone analogs with antitumor activity

Pyrrolizinones represent an interesting class of compounds with varied degrees of structural complexity and pharmacological activity. Among these, 9H-pyrido[2,3-b]pyrrolizin-9-one, tripentone analogs, recently reported by us, showed significant antiproliferative activity against human tumor cell lines, inducing apoptosis and not affecting viability of Caco-2 differentiated in normal intestinal-like cells. Considering their interesting biological activity, their 5H-pyrido[3,2-b]pyrrolizin-5-one analogs were efficiently synthesized in good to excellent yields (61–91%). All tripentone derivatives were tested to assess their cytotoxicity against two human tumor cell lines, HCT-116 (human colorectal carcinoma) and MCF-7 (human breast cancer). The most active derivatives, with IC50 ranging from 0.11 to 16.11 μM, did not affect viability of Caco-2 differentiated in normal intestinal-like cells, suggesting tumor cells as the main target of their cytotoxic action. The same compounds, further investigated, showed that they did not exert necrotic effects, while induced a clear shift of viable cells towards early apoptosis confining the cells in the mitotic phases.

Synthesis, crystal structure, and DFT study of a new pyrido[2,3-d]pyrimidine compound 1-(4-((6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy) phenyl)-3-(2,4-difluorophenyl)urea

In this study, 1-(4-((6-bromopyrido[2,3-d]pyrimidin-4-yl)oxy)phenyl)-3- (2,4-difluorophenyl) urea was synthesized. The structure of the compound was determined by mass spectrometry and 1H NMR, 13C NMR and FT-IR spectroscopy. The solid-state structure of the title compound was determined using single-crystal X-ray diffraction and the optimized molecular structure was determined using density functional theory calculations. The conformation of the most stable isomer that was calculated at room temperature was consistent with the conformation derived from X-ray diffraction. Hirshfeld surface analysis and 2D fingerprints were used to quantitatively analyze the intermolecular interactions and contacts in the crystal structure.

Pyrido[2,3-d]pyrimidine compound as well as preparation method and application thereof

The present invention discloses a pyrido[2,3-d]pyrimidine compound represented by a general formula I or a pharmaceutically acceptable salt thereof. The general formula I is shown as the specification, wherein R1 is selected from one of an alkylamine group of C1-C6, an alicyclic amine group of C1-C6, a heterocyclic amine group of C1-C6, and an aromatic amine group of C6-C8, and X represents a hydrogen atom or a halogen atom. According to the invention, in-vitro cell activity tests prove that the compound provided by the invention has antitumor activity and can be used for preparing medicines for treating and/or preventing various cancers caused by BRaf kinase mutation, such as melanoma, thyroid cancer, breast cancer, liver cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, etc.